Patent · US Active

Humanized antibodies for CD3

US11472880B2 · kind B2 · utility

0Cited by

0References

15Claims

0Family size

Assignee

MORPHOSYS AG · DE

Inventors

Thomas Tiller · Munich, DE
Steffen Runz · Heidelberg, DE
Julia Neugebauer · Munich, DE
Andreas Bültmann · Planegg, DE

Key dates

Filing date	Aug 13, 2018
Grant date	Oct 18, 2022
Priority date	—
Expiry date	Dec 16, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells. The present disclosure also provides bispecific antibodies comprising a first antigen-binding domain that specifically binds to human CD3 with optimized affinity and a second antigen-binding molecule that specifically binds a tumor-related antigen. The disclosure further relates to methods of generating such humanized antibodies and bispecific antibodies for biological, diagnostic, pharmaceutical and other uses.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.